First-line tepotinib for a very elderly patient with metastatic NSCLC harboring <i>MET</i> exon 14 skipping mutation and high PD-L1 expression.

First-line tepotinib for a very elderly patient with metastatic NSCLC harboring MET exon 14 skipping mutation and high PD-L1 expression.

Inno, Alessandro; Bogina, Giuseppe; Settanni, Giulio; Salgarello, Matteo; Foti, Giovanni; Pomari, Carlo; Picece, Vincenzo; Gori, Stefania.

Afiliación

Inno A; Medical Oncology Unit, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar di Valpolicella (VR) - Italy.
Bogina G; Pathology Unit, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar di Valpolicella (VR) - Italy.
Settanni G; Pathology Unit, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar di Valpolicella (VR) - Italy.
Salgarello M; Nuclear Medicine Unit, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar di Valpolicella (VR) - Italy.
Foti G; Radiology Unit, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar di Valpolicella (VR) - Italy.
Pomari C; Pulmonology and Thoracic Endoscopy Unit, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar di Valpolicella (VR) - Italy.
Picece V; Medical Oncology Unit, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar di Valpolicella (VR) - Italy.
Gori S; Medical Oncology Unit, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar di Valpolicella (VR) - Italy.

Drug Target Insights ; 17: 110-113, 2023.

Article en En | MEDLINE | ID: mdl-37840886